BMS-191095

BMS-191095 is a selective activator of mitochondrial ATP-sensitive potassium (mitoKATP) channels. BMS-191095 inhibits human platelet aggregation by opening mitochondrial K (ATP) channels[1][2][3].

Product Specifications

CAS Number

[166095-21-2]

UNSPSC

12352005

Target

Potassium Channel

Type

Reference compound

Related Pathways

Membrane Transporter/Ion Channel

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Neurological Disease; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/BMS-191095.html

Purity

98.01

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

CC(O1)(C)[C@H](O)[C@@H](N(CC2=NC=CN2)C3=CC=C(Cl)C=C3)C4=C1C=CC(C#N)=C4

Molecular Formula

C22H21ClN4O2

Molecular Weight

408.88

References & Citations

[1]Katakam PV, et al. Diversity of mitochondria-dependent dilator mechanisms in vascular smooth muscle of cerebral arteries from normal and insulin-resistant rats. Am J Physiol Heart Circ Physiol. 2014 Aug 15;307 (4) :H493-503.|[2]Cho MR, et al. BMS-191095, a cardioselective mitochondrial K (ATP) opener, inhibits human platelet aggregation by opening mitochondrial K (ATP) channels. Arch Pharm Res. 2005 Jan;28 (1) :61-7.|[3]Mayanagi K, et al. The mitochondrial K (ATP) channel opener BMS-191095 reduces neuronal damage after transient focal cerebral ischemia in rats. J Cereb Blood Flow Metab. 2007 Feb;27 (2) :348-55.